[Compound erythromycin sustained release preparation and its in vitro release]

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Materials Science

Background:

• Developing sustained-release formulations is crucial for improving therapeutic efficacy and patient compliance.
• Polylactic acid (PLA) is a biocompatible and biodegradable polymer widely used as a drug carrier.
• Erythromycin (EM) and prednisone acetate (PNA) are commonly prescribed drugs requiring controlled release for optimal treatment.

Purpose of the Study:

• To prepare and characterize a novel sustained-release tablet formulation containing erythromycin (EM) and prednisone acetate (PNA).
• To evaluate the in vitro drug release kinetics of EM and PNA from the polylactic acid (PLA)-based sustained-release tablets.
• To assess the feasibility and potential clinical efficacy of the developed sustained-release preparation.

Main Methods:

• A sustained-release tablet was prepared by mixing polylactic acid (PLA) with erythromycin (EM) and prednisone acetate (PNA).
• In vitro drug release studies were conducted using ultraviolet spectrophotometry and high-performance liquid chromatography (HPLC) to quantify EM and PNA release over 21 days.
• Analysis of drug content and release profiles was performed to determine formulation performance.

Main Results:

• The sustained-release tablets exhibited drug release for approximately 21 days.
• Average drug content was 99.7 mg/tablet for EM (RSD=0.82%) and 10.03 mg/tablet for PNA (RSD=0.93%).
• Cumulative release of EM and PNA reached 86.1% and 78.3%, respectively, within 21 days, with steady release after an initial burst effect.

Conclusions:

• The developed sustained-release tablet preparation method using PLA is feasible.
• The formulation demonstrates good drug release performance, characterized by slow and steady release after an initial burst.
• The sustained-release tablets show significant potential for clinical efficacy due to their favorable release characteristics.